Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL

Leukemia

Volumn 25, Issue 10, 2011, Pages 1564-1569

  Sulis, M L ^a   Saftig, P ^b   Ferrando, A A ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

ADAM10; ADAM17; NOTCH1; T ALL

Indexed keywords

ADAM10 ENDOPEPTIDASE; NOTCH1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ALLELE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHATIC LEUKEMIA; LYMPHOBLAST; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; T CELL LYMPHOBLASTIC LEUKEMIA; WILD TYPE;

EID: 80054045386     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.130     Document Type: Article

References (30)

1. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009; 1: 353-361.
2. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25: 83-90.
3. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011; 223: 262-273.
4. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613. (Pubitemid 351488294)
5. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689. (Pubitemid 44268213)
6. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271. (Pubitemid 39336870)
7. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, Aster JC et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 2006; 26: 4642-4651. (Pubitemid 43877581)
8. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008; 112: 733-740.
9. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 2008; 14: 5314-5317.
10. Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 1997; 90: 271-280. (Pubitemid 27329712)
11. Sotillos S, Roch F, Campuzano S. The metalloprotease-disintegrin Kuzbanian participates in Notch activation during growth and patterning of Drosophila imaginal discs. Development 1997; 124: 4769-4779. (Pubitemid 28014380)
12. Wen C, Metzstein MM, Greenwald I. SUP-17, a Caenorhabditis elegans ADAM protein related to Drosophila KUZBANIAN, and its role in LIN-12/NOTCH signalling. Development 1997; 124: 4759-4767. (Pubitemid 28014379)
13. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000; 5: 207-216. (Pubitemid 30628080)
14. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ et al. A ligand-induced extracellular cleavage regulates gammasecretase-like proteolytic activation of Notch1. Mol Cell 2000; 5: 197-206. (Pubitemid 30628079)
15. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002; 11: 2615-2624. (Pubitemid 35174691)
16. Manilay JO, Anderson AC, Kang C, Robey EA. Impairment of thymocyte development by dominant-negative Kuzbanian (ADAM-10) is rescued by the Notch ligand, delta-1. J Immunol 2005; 174: 6732-6741. (Pubitemid 40705635)
17. Tian L, Wu X, Chi C, Han M, Xu T, Zhuang Y. ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int Immunol 2008; 20: 1181-1187.
18. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 2009; 284: 31018-31027.
19. Bozkulak EC, Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009; 29: 5679-5695.
20. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-1298.
21. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043. (Pubitemid 351389536)
22. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50-58.
23. Palomero T, Barnes KC, Real PJ, Glade Bender JL, Sulis ML, Murty VV et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia 2006; 20: 1279-1287. (Pubitemid 43905832)
24. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-1057.
25. Aste-Amezaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS ONE 2010; 5: e9094.
26. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8: 929-941.
27. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43. (Pubitemid 40064897)
28. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-134. (Pubitemid 46386405)
29. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50. (Pubitemid 44018087)
30. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007; 117: 337-345. (Pubitemid 46203962)